Evidence map›Paper›PMID 40605158›Full record

ReviewCurrent pharmaceutical design2026

Sugammadex in Perioperative Neuromuscular Management: Current Advances and Best Practices.

Xuehua Zhou, Xia Shen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Sugammadex-Associated Delayed Laryngeal and Upper Airway Edema: A Novel Adverse Effect.Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xuehua ZhouDepartment of Anesthesiology, Eye & ENT Hospital, Fudan University, 83 Fenyang Road, Shanghai, Yangpu, 200031, China.
Xia ShenDepartment of Anesthesiology, Eye & ENT Hospital, Fudan University, 83 Fenyang Road, Shanghai, Yangpu, 200031, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuromuscular blocking agents (NMBAs) are crucial for anesthesia, enabling intubation and optimal surgical conditions. Timely reversal of blockade is critical for safe extubation and recovery. While neostigmine, a traditional reversal agent, is effective for moderate blockade, it has limitations in reversing deep blockade and requires anticholinergics to mitigate side effects. Sugammadex, a novel agent, addresses these limitations by selectively encapsulating aminosteroid NMBAs like rocuronium, providing rapid and reliable reversal. It demonstrates significant advantages, including faster recovery and reduced postoperative complications, especially in high-risk populations such as elderly patients or those with organ dysfunction. However, challenges such as high costs and potential adverse effects, including hypersensitivity and cardiovascular events, restrict its routine use. This review explores sugammadex's pharmacological features, clinical applications, and cost-effectiveness, offering strategies to optimize its use in complex surgical scenarios while addressing current limitations.

Indexed as

gamma-CyclodextrinsNeuromuscular BlockadeNeuromuscular Nondepolarizing AgentsPerioperative CareSugammadexHumansgamma-CyclodextrinsNeuromuscular Nondepolarizing AgentsSugammadexadverse reactionsclinical application.cost-effectivenessneostigmineNeuromuscular blockadesugammadex

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.